Clair Health Pitch Deck: All 13 Slides + Teardown

Clair Health's 13-slide deck is a masterclass in using early momentum to de-risk a complex hardware and healthcare play. By reporting 5,600+ pre-orders and a 23,000+ person waitlist just nine weeks after emerging from stealth, the company shifts the investor conversation from 'will people want this?' to 'how fast can we scale?' The deck balances consumer-facing hype with institutional credibility, citing a network of clinical partners and a team with backgrounds at the FDA, Apple, and Stanford Medicine. While the deck is light on specific unit economics and long-term competitive moats, the sh…

Key takeaways

• The company claims the title of 'World's first wearable hormone monitor' on Slide 1, establishing a clear category-leading position.
• Clair identifies a $100B market opportunity linked to four specific hormones that are currently untracked, according to Slide 2.
• Traction is the primary focus, with Slide 3 highlighting 5,600+ pre-orders and a 23,000+ waitlist within nine weeks of launch.
• The deck leans heavily on B2B credibility, citing 'B2B device purchase MOUs' on Slide 4 and a network of clinical partners on Slide 5.
• A November launch date is explicitly stated on Slide 5, providing a clear timeline for near-term milestones.
• The team slide (Slide 7) emphasizes regulatory and technical expertise with logos from the FDA, Meta, Apple, and Stanford Medicine.
• Slide 13 claims the technology is 'validated against gold-standard hormone assays in a real-world clinical trial,' addressing technical risk.
• The deck omits specific financial projections, unit economics, and a detailed breakdown of the $11.6M use of funds, as seen on Slide 9.

Frequently asked questions

How does Clair Health prove there is demand for a hormone wearable?

Clair Health uses Slide 3 to showcase immediate market validation. They report over 5,600 pre-orders and a waitlist exceeding 23,000 people, all achieved within nine weeks of exiting stealth mode. A cumulative growth chart visually reinforces this rapid adoption, suggesting that the consumer appetite for hormone tracking is significant and underserved by existing wearables.

What specific hormones does the Clair device track?

While Slide 2 mentions that $100B in health outcomes are tied to four hormones, the specific names are not listed on that slide. However, Slide 13 shows app mockups tracking Estrogen, Progesterone, LH (Luteinizing Hormone), and FSH (Follicle-Stimulating Hormone). The device aims to provide a 'continuous window' into these levels rather than the point-in-time data offered by traditional blood tests.

Is the Clair Health device FDA cleared?

The deck does not explicitly state that the device has received FDA clearance. However, Slide 7 highlights 'regulatory experts' on the team and includes the FDA logo among their background credentials. Slide 11 also references FDA guidance for 'general wellness policy-low-risk devices,' suggesting the company may be pursuing a wellness classification or is currently navigating the regulatory pathway.

What is the company's go-to-market strategy?

Clair Health employs a dual-track strategy. Slide 3 demonstrates a strong Direct-to-Consumer (DTC) pull through pre-orders. Simultaneously, Slides 4 and 5 highlight a B2B approach, mentioning 'B2B device purchase MOUs' and a 'network of clinical partners' intended to drive user adoption and integrate with existing healthcare software via APIs.

What are the primary risks addressed in the deck?

The deck addresses two main risks: market risk and technical risk. Market risk is countered by the high volume of pre-orders (Slide 3). Technical and clinical risk is addressed on Slide 13, where the company claims its 'female biology model' has been validated against 'gold-standard hormone assays' in clinical trials, though specific trial data is not provided in the main slides.

Clair Health pitch deck: the facts

Company

Clair Health

Year

2024

Stage

Seed

Slides

13

Sector

Healthcare, Consumer electronics

Deck type

Seed Pitch Deck

Outcome

$11.6M Raised

Headquarters

San Francisco, N. America

Clair Health pitch deck PDF

The full Clair Health deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Clair Health pitch deck was used for

This pitch deck is for Clair Health, a women’s health technology startup building a wrist‑worn, noninvasive continuous hormone monitor for women, paired with a companion mobile app[2][4][5][14][15]. The deck is described as a seed‑stage fundraise, associated with an $11.6M round led by Khosla Ventures to build and launch the device and accelerate research and clinical validation[1][3][4][5][7][8][10][13][14]. It emphasizes a very large waitlist (25,000+ prospective users), clinical trial plans through Stanford, and B2B partnerships using APIs ahead of a planned November launch of the wellness product[4][10][14][15]. The deck also frames Clair as the first continuous, noninvasive hormone monitor and highlights its biosensor stack, proprietary sensor‑fusion models, and female biology “world model” delivering app‑based insights[2][5][14][15].

Business model: Develops a noninvasive, wrist‑worn consumer wearable that provides continuous hormone insights for women, paired with a mobile app and APIs for partners[2][5][9][14][15].

Round

Seed[1][3][4][5][7][8][11].

Lead investor

Khosla Ventures[1][3][4][5][7][8][13][14].

Investors

Khosla Ventures, a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, Anne Wojcicki[1][3][4][5][7][8][10][13][14].

Founders

Jenny Duan, Abhinav Agarwal[1][3][4][5][10].

Headquarters

Mountain View, California[15].

Year: 2026[1][3][4][5][7][8][10][13][14].

Raised: $11.6M seed round in June 2026[1][3][4][5][7][8][10][13][14].

Industry: Women’s health technology; healthcare hardware / wearable consumer electronics[2][5][11][15].

Total funding: At least $11.6M in seed funding raised in June 2026, following an earlier pre‑seed round mentioned by the CEO[1][3][4][5][7][8][10][13][14][12].

Use of funds as presented: To develop and launch Clair’s noninvasive wrist‑worn continuous hormone monitor and companion app, support further research and clinical trials, and scale commercialization ahead of the planned November launch[1][3][4][5][10][14].

What happened after the Clair Health deck

Following its $11.6M seed round led by Khosla Ventures, Clair Health has built a wrist‑worn, noninvasive continuous hormone monitor for women, attracted a large waitlist and early revenue, and is preparing for a November 2026 wellness launch while pursuing clinical validation and future FDA clearance[1][2][4][5][7][8][10][13][14][15].

• Raised a $11.6M seed round in June 2026 led by Khosla Ventures, with participation from a16z Speedrun, Brydge Club, Tree
• Reported more than 25,000 individuals on its waitlist ahead of the planned November 2026 launch of its wrist‑worn device
• Announced early traction of approximately $800K in direct‑to‑consumer revenue and $18M in B2B contracts signed in less t
• Outlined plans for an independent clinical trial through Stanford’s Gladstone BeeHive program, with intent to publish pe

What the Clair Health deck got right

• Clear, differentiated product for an underserved need in women’s health. Clair offers a **distinctive product vision**: a jewelry‑like wrist wearable that provides continuous, noninvasive hormone insights for women, filling a well‑recognized gap in women’s health where hormone data is typically episodic and invasive[2][4][5][10][14][15].
• Compelling early traction and demand signals. The deck and external coverage highlight a **large waitlist (23,000–25,000+ signups)** and significant early traction—including hundreds of thousands of dollars in D2C revenue and eight‑figure B2B contracts signed rapidly—which strongly signal demand and business momentum[4][10][14][15].
• Sophisticated biosensing and AI narrative. Clair’s technology story combines a **10‑biosensor stack, 130+ biomarkers, sensor‑fusion AI, and a female biology world model** to infer hormone levels without blood, urine, or saliva, which presents a sophisticated and defensible technical narrative for investors[2][5][14][15].
• Proactive clinical validation strategy. The company communicates plans for **independent clinical trials via Stanford’s Gladstone BeeHive program and peer‑reviewed publication**, directly addressing scientific skepticism and bolstering credibility in regulated‑adjacent health tech[4][10][14].
• High‑signal seed investor syndicate. A strong investor syndicate led by **Khosla Ventures**, with participation from a16z Speedrun and prominent healthcare investors including Anne Wojcicki, gives Clair substantial signaling value and suggests institutional confidence in the team and thesis[1][3][5][7][8][10][13][14].
• Platform framing with both consumer and B2B optionality. The deck frames Clair as a **platform**—consumer hardware, mobile app, partner APIs, and a biology model—supporting both D2C and B2B revenue, which can be attractive to investors seeking diversified, scalable business models[2][4][5][9][14][15].

What could have been stronger

• Limited competitive landscape detail despite strong “first” claims. The deck positions Clair as the “world’s first” or “first” continuous hormone monitor, but press and company profiles do not clearly benchmark against emerging competitors in hormone‑aware wearables or advanced fertility monitoring, leaving investors to do their own competitive mapping[2][5][8][14][15].
• Traction metrics lack depth on long‑term engagement and economics. While the deck and external coverage emphasize a 23,000–25,000+ person waitlist and strong early revenue and B2B contracts, there is little visible detail on retention, engagement, cohort behavior, or unit economics, which are critical for hardware plus subscription models[4][10][14][15].
• Sparse quantitative validation summary relative to the scientific ambition. Clair’s science narrative relies on proprietary sensor‑fusion and a female biology world model, but public descriptions of validation are high‑level; investors may find limited accessible data in the deck on accuracy benchmarks versus gold‑standard lab hormone assays across diverse populations[1][2][4][5][10][14][15].
• Regulatory path is mentioned but not thoroughly mapped out. The company plans to launch first as a wellness product and pursue FDA clearance later, yet the deck (and media) do not appear to deeply detail regulatory strategy, timelines, or classification pathways, which may concern investors wary of regulated hardware[4][5][10][14].
• Customer segmentation and GTM focus appear under‑specified. The deck highlights a large waitlist and founding‑member offers, but does not clearly separate signals generated by PR virality from durable demand or provide segmentation by life stage (fertility, perimenopause, etc.), leaving uncertainty about target customer focus and go‑to‑market prioritization[2][4][5][10][14][15].

How an investor would read this deck

What draws attention

• Claims of being the **first continuous, noninvasive hormone monitor for women**, supported by a custom biosensor stack and AI‑driven hormone inference, represent a differentiated technical and product thesis in women’s health wearables[2][5][14][15].
• A **large reported waitlist (23,000–25,000+ signups)** and early D2C revenue plus sizable B2B contracts within weeks indicate strong initial market pull and a potentially compelling blend of consumer and enterprise demand[4][10][14][15].
• The founding team—Stanford‑trained founders with visible media presence—and backing from **tier‑one investors such as Khosla Ventures, a16z Speedrun and Anne Wojcicki** suggest high signaling value and access to capital and networks[1][3][5][7][8][10][13][12].
• The deck’s emphasis on **clinical validation**, including an independent trial through Stanford’s Gladstone BeeHive program and intent to obtain peer‑reviewed publication, directly targets a common investor concern about the robustness of novel biosensing hardware[4][10][14].
• Clair’s platform framing—wearable hardware, mobile app, APIs for partners, and a female biology world model—suggests extensibility beyond a single SKU towards recurring software revenue and research/clinical partnerships[2][4][5][9][14][15].

Risks that stand out

• Scientific and technical risk that noninvasive biosensing plus AI may not achieve clinically reliable hormone readings across diverse populations, which could limit medical use cases or invite regulatory scrutiny despite wellness positioning[1][2][4][5][10][14][15].
• Regulatory risk given the plan to start as a wellness product and pursue FDA clearance later; shifting guidance or enforcement could constrain marketing claims or delay B2B deployments in more clinical contexts[4][5][10][14].
• Execution risk in hardware manufacturing, quality assurance, and supply chain, as delays or hardware reliability issues could erode trust among early adopters and B2B partners and impact revenue ramp[2][5][14][15].
• Market‑education risk: continuous hormone monitoring is a novel category; substantial investment may be required to educate consumers and providers on interpreting hormone insights and translating them into actionable health behavior[2][4][5][10][14][15].
• Competitive risk that other women’s health or wearable companies enter the hormone‑aware space with simpler or more established modalities (e.g., lab‑integrated testing, hybrid solutions), diluting Clair’s “first” positioning and pricing power[2][5][8][14][15].

Questions this deck invites

• What quantitative validation data (sensitivity, specificity, correlation coefficients vs. gold‑standard hormone assays) exist today for Clair’s sensor‑fusion model across different age groups, skin tones, and health conditions, and how will
• How durable is the reported early traction—what are conversion, activation, retention, and churn metrics for waitlist members and paying customers, and what evidence supports long‑term subscription engagement beyond the founding‑member prom
• What are Clair’s gross margin structure and unit economics (hardware COGS, subsidy strategy, app subscription pricing, support costs), and how do these compare to analogous wearables like Oura or Whoop once scaled manufacturing is in place[
• What is the detailed regulatory roadmap (device classification, intended indications, trial design, endpoints, timelines) for transitioning from wellness positioning to FDA‑cleared medical claims, and how might this affect marketing, B2B de
• How defensible are Clair’s biosensor stack and AI models from an IP perspective (patents filed, trade secrets, data moat), and what is the risk that larger incumbents in wearables or diagnostics could replicate hormone inference capabilitie

What founders can take from the Clair Health deck

• Anchoring a hardware+health pitch around a **clear, first‑of‑its‑kind claim** (continuous, noninvasive hormone monitor for women) can help investors quickly place the company within a crowded wearable landscape, provided that supporting technical detail is available[2][5][14][15].
• Showing **large, concrete traction numbers** like a 23,000–25,000+ person waitlist and named revenue figures for D2C and B2B can make early demand tangible, but investors will still expect deeper metrics on behavior and economics[4][10][14][15].
• Positioning a regulated‑adjacent product as **wellness first, then medical** can frame a faster path to market, yet it is important that decks outline regulatory strategy sufficiently to reassure investors about long‑term defensibility[4][5][10][14].
• Integrating **clinical validation narratives** (independent trials, peer‑review plans, collaboration with academic programs) directly into the deck is a powerful way to address skepticism about novel biosensing, especially in women’s health where evidence gaps are common[4][10][14].
• Combining a **platform story**—hardware, app, APIs, and a biology world model—with specific early B2B partnerships helps investors see optionality beyond consumer sales and the potential for diversified revenue streams[2][4][5][9][14][15].
• Media coverage and investor profiles that echo key deck themes (continuous hormone intelligence, women‑focused design, biosensor stack) demonstrate how a coherent narrative can propagate across press, investor sites, and the company website to reinforce positioning[1][2][4][5][8][10][14][15].

Clair Health pitch deck: common questions

What does Clair Health do?

Clair Health is a women’s health technology startup developing a **wrist‑worn, noninvasive continuous hormone monitor** for women, combined with a mobile app that turns physiological signals into real‑time hormone insights[2][4][5][14][15]. The bracelet uses multiple biosensors and AI models to help women understand and optimize their health across life stages such as menstruation, fertility, and menopause[2][5][10][14][15].

How much money has Clair Health raised and who invested?

Public reporting indicates Clair raised **$11.6M in seed funding in June 2026**, in a round led by Khosla Ventures with participation from a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, Anne Wojcicki and other health‑focused investors[1][3][5][7][8][10][13][14]. Earlier statements by CEO Jenny Duan reference a pre‑seed round led by a16z Speedrun and Reach Capital, but those amounts are not disclosed[12].

How does Clair’s hormone‑monitoring bracelet work and which hormones does it track?

Clair’s wrist wearable is designed to track **estrogen, progesterone, LH, FSH, and PdG** by combining readings from a stack of 10 biosensors with a proprietary sensor‑fusion model and a female biology world model[2][5][14][15]. It infers hormone levels noninvasively from signals such as skin temperature, heart rate variability, electrodermal activity and other biomarkers, rather than using blood, urine, or saliva[2][5][14].

When is Clair Health’s device launching, and is it a regulated medical device?

Clair describes its initial product launch as a **wellness device**, with plans for a **November 2026** commercial launch of the bracelet and companion app, followed by pursuit of FDA clearance[4][5][10][14]. The company reports more than **25,000 people on its waitlist** ahead of launch and is offering founding‑member preorders that ship in December 2026 according to its website[2][4][10].

What is Clair Health’s business model and traction so far?

Media coverage and company statements describe Clair’s current focus as **direct‑to‑consumer sales to women plus B2B partnerships** with research and health organizations[2][4][5][9][14][15]. The a16z Speedrun company profile cites **$800K in direct‑to‑consumer revenue and $18M in B2B contracts signed in under eight weeks**, and Clair’s partner materials highlight APIs that integrate with existing software for seamless adoption[9][15].

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• Stanford Grads Secure $11.6 Million for Women's Hormone ...
• Clair Health | The First Continuous Hormone Monitor — Track ...
• Two Stanford grads raise $11M to build a noninvasive wearable for ...
• Clair Health Raises $11.6 Million to Develop Continuous ...
• Exclusive: A 21-year-old Stanford grad just raised $11 ...
• About Clair Health | The Team Behind Continuous Hormone Monitoring
• Clair Health Inc. Asset Profile | Preqin
• Clair Health • Company Profile - New AI Health

Clair Health pitch deck slides

What each slide of the Clair Health pitch deck says

Slide 2

$100B in women's health outcomes come down to four hormones. Nobody's tracking them. E Fertility Hormone Health strogen 1in6 couples struggle to PCOS and endometriosis take Progesterone E conceive (elt ves dane LH FSH Perimenopause Longevity Women spend $13B/year on Estrogen loss after menopause symptom management. doubles cardiovascular risk within 10 years. 1

Slide 3

Since coming out of stealth Cumulative Pre-orders nine weeks ago, we have a: Cumulative Pre-orders waitlist preorders —

Slide 4

I BB device purchase MOUs REPRESENTING Across distribution and clinical partners. Shipping late 2026.

Slide 5

We've built a network of ahead of our November launch Our partners drive user adoption and B2B partnerships. APIs integrate with existing software for seamless adoption.

Slide 12

Clair tums a wrist-worm wearable into the first continuous window into female bormones « Powered by a 10-biosensor stack that tracks 130+ biomarkers from the wrist without blood, urine, or H saliva « Our sensor fusion model turns these signals into continuous hormone readings « Insights are delivered from our female biology world model to users via mobile app

Slide text above is read directly from the Clair Health deck PDF embedded on this page.

Related fundraising guides (24)

• Innovafeed Pitch Deck Teardown: A $250M Masterclass in Industrial Scale and Strategic Partnerships
• Brag House Pitch Deck Teardown: Targeting the Casual Collegiate Esports Market
• Hervé Pitch Deck Teardown: Scaling Luxury Cannabis Edibles Through Proprietary Hardware
• Amogy Pitch Deck Teardown: Solving the Energy Density Gap for Heavy-Duty Mobility
• Examedi Pitch Deck Teardown: A Lean Vision for Latin American Healthcare Logistics
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• Ideon Technologies Pitch Deck Teardown: Using Muon Tomography to De-Risk Mining Exploration
• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility
• Alcatraz AI Pitch Deck Teardown: Leveraging Apple FaceID Pedigree for Enterprise Security
• EVERY Pitch Deck Teardown: A $175M Masterclass in Precision Fermentation Storytelling
• Cove.Tool Pitch Deck Teardown: A Masterclass in Visualizing Efficiency Gains
• Craft.io Pitch Deck Teardown: A $8M Series A Masterclass in Product-Led Narrative
• Vespa.ai Pitch Deck Teardown: A Corporate Spin-Out Strategy for High-Scale Vector Search
• Chptr Pitch Deck Teardown: Modernizing the $120B Death Industry for Digital Natives
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Auki Labs Pitch Deck Teardown: A $13M Bet on Replacing GPS for the Spatial Metaverse
• Groundcover Pitch Deck Teardown: Leveraging eBPF to Disrupt Cloud Observability Costs
• AgomAb Therapeutics Pitch Deck Teardown: A Masterclass in Biotech Pipeline Visualization
• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering

This deck's categories (1)

• Seed & Pre-Seed Pitch Deck Examples

Decks from the same year (1)

• 2024 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $10M to $50M

Browse companies alphabetically (1)

• Pitch decks from companies starting with C

Decks in the same category (12)

• Agile Wash Pitch Deck Breakdown: Four Real Slides In A 37-Page Template
• TransferWise (Wise) Pitch Deck Breakdown
• Foursquare Seed Pitch Deck Breakdown
• Revolut Pitch Deck Breakdown
• Mint.com 2007 Seed Pitch Deck Breakdown
• Intercom Pitch Deck Breakdown: How to Sell a Category-Defining Vision
• SendGrid Pitch Deck Breakdown: A Masterclass in B2D Simplicity
• Exeq Pitch Deck Breakdown: The 2017 Consumer Fintech Deck That Left Its Business Model in Another File
• DocSend Pitch Deck Research Breakdown
• HomeCooks Pitch Deck Breakdown: 25 Slides Of Real Revenue And Three Slides That Disagree About The Future
• Qeep Pitch Deck Breakdown: The Business Plan With No Business In It
• Tinder (Match Box) Pitch Deck Breakdown

More pitch deck teardowns (16)

• CityScale Pitch Deck Teardown: A Data-Driven Approach to Post-War Housing and Urban Planning
• Civicrowd Pitch Deck Teardown: A Solo-Founder Play for European Civic Crowdfunding
• Claap Pitch Deck Teardown: How a Pre-Product Team Raised $3M on Asynchronous Workflow
• Claap Pitch Deck Breakdown: Defining the Asynchronous Meeting Category
• Cladwell Pitch Deck Breakdown: A Minimalist Approach to Scaling Sustainable Fashion Tech
• ClaimCompass Pitch Deck Breakdown: A Masterclass in High-Signal, Low-Noise Seed Fundraising
• Claira Pitch Deck Teardown: Solving the Legal Logic Gap in Financial Contracts
• Claire Pitch Deck Teardown: A Dual-Sided AI Recruitment and Coaching Marketplace
• Clair Pitch Deck Breakdown: The Embedded FinTech Play for On-Demand Pay
• Clanbeat Pitch Deck Breakdown: Leveraging Founder Pedigree to Solve the $40,000 Retention Gap
• clare&me Pitch Deck Breakdown: Solving Mental Health Scarcity with AI Audio Bots
• Clari Pitch Deck Breakdown: A Masterclass in Category Creation and Enterprise Social Proof
• Clarity Pitch Deck Breakdown: Solving the Career Mismatch for Women in Japan
• Clark Pitch Deck Breakdown: A Masterclass in Market Disruption and Brand Awareness
• Claroty Pitch Deck Breakdown: Securing the Industrial Economy with OT Visibility
• CleanHub Pitch Deck Teardown: Turning Non-Recyclable Waste Into a $170bn Market Opportunity

Recently published pitch deck teardowns (12)

• Grasp Pitch Deck Teardown: Targeting the $1.4T Financial Advisory Market with Domain-Specific AI
• Gutsy Pitch Deck Teardown: A $51M Seed Masterclass in Process Mining for Security
• Groundcover Pitch Deck Teardown: Leveraging eBPF to Disrupt Cloud Observability Costs
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility
• Handly Pitch Deck Teardown: A B2B2C Play for the €5 Trillion Craft Services Market
• Happy Health Pitch Deck Teardown: A $75M Masterclass in Vertically Integrated Sleep Care
• Harmony Pitch Deck Teardown: A $34M Seed Round Built on Founder Pedigree and Rapid Adoption
• Hashtag Pay Me Pitch Deck Teardown: A 9-Slide Masterclass in Pre-Seed Traction
• HMNC Brain Health Pitch Deck Teardown: A Precision Psychiatry Play for Depression
• Hintsa Pitch Deck Teardown: A $5.2M Masterclass in High-Performance Wellness Branding
• Heura Pitch Deck Teardown: Dominating the Mediterranean Plant-Based Market
• Holdbar Pitch Deck Teardown: Leveraging Founder Exit Credibility for a $3.5M Seed

Fundraising library · Pitch deck examples · Investor directory · Founder database